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e development, testing, and adoption into clinical practice
of anticancer medications have revolutionized cancer care
over the past decades. A better understanding of the biology
of cancer has translated into development of novel systemic
agents, as well a more eﬀective use of older chemotherapy
agents. As a consequence, cancer mortality continues to
decrease.
However, greater cure and disease control rates come at
a price of an increased risk of adverse eﬀects, which o	en
aﬀects the mouth and related structures including the oral
mucosa, salivary glands, jawbones, and cranial nerves. Oral
mucositis, hyposalivation, dysgeusia, and osteonecrosis of
the jaw (ONJ) are some examples of the potential adverse
eﬀects of anticancer therapies to the oral cavity, which aﬀect
an increasing number of individuals living with cancer and
cancer survivors and can lead to persistent discomfort, pain,
dysfunction, and a notable reduction in the quality of life.
Management of these oral adverse eﬀects can be challenging,
as it typically requires a multidisciplinary approach and a
close collaboration between the cancer team and oral health
care providers, both in primary care and in the specialist
setting.
is special issue provides a useful update of some of the
most signiﬁcant adverse reactions to anticancer drugs in the
oral cavity, with a view to inform clinical practice and inspire
further research.
Multitargeted tyrosine kinase inhibitors including suni-
tinib, sorafenib, axitinib, and cabozantinib are increasingly
used in the cancer setting, and C. Arena et al. provide in
this special issue a useful systematic review on oral mucositis
associated with these agents. Similarly, K. Pimolbutr et al.
report on the development of ONJ associated with antiangio-
genic agents in the subset of antiresorptive-naı¨ve patients.
Prevention of toxicity is crucial in individuals due to
commence and in those who have been using antiresorptive
medications, and O. Di Fede et al. discuss the main strategies
to reduce the risk ONJ in this patient population.
e surgical treatment of medication-related ONJ is a
relatively new ﬁeld of research, as this condition has been
historically managed conservatively with a focus on pain
management and resolution of infection. In this special issue,
R. Mauceri et al. report on the use of Er,Cr:YSGG laser and
platelet-rich plasma in the surgical treatment ofONJ, whereas
R. Sacco et al. provide a systematic review of the eﬃcacy of
microsurgical reconstruction of the jaws using vascularized
free ﬂap in patients with medication-related ONJ.
We hope that the readers of BioMed Research Interna-
tional will ﬁnd this special issue interesting and informative.
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